HAMLET PROTEIN A/S - CVR: 16049441

2022, DKK

12.05.2023

Bruttoresultat

-7.135'

Primær drift

-93.460'

Årets resultat

-87.791'

Aktiver

524''

Kortfristede aktiver

309''

Egenkapital

59.375'

Afkastningsgrad

-18 %

Soliditetsgrad

11 %

Likviditetsgrad

67 %

Resultat

12.05.2023

Årsrapport	2022 12.05.2023	2021 12.07.2022	2020 31.05.2021	2019 30.06.2020	2018 04.06.2019	2017 28.03.2018	2016 16.05.2017	2015 09.05.2016
Nettoomsætning	452.988.000	481.036.000	491.884.000	363.535.000	413.019.000	402.243.000	399.148.000	441.046.000
Bruttoresultat	-7.135.000	52.477.000	92.928.000	76.336.000	71.949.000	97.541.000	99.096.000	0
Resultat af primær drift	-93.460.000	-19.938.000	14.028.000	-38.632.000	-10.970.000	-8.952.000	8.184.000	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	5.859.000	11.958.000	6.428.000	6.675.000	8.707.000	6.060.000	8.996.000	5.016.000
Finansieringsomkostninger	0	0	0	0	0	0	-9.928.000	-10.618.000
Andre finansielle omkostninger	-21.884.000	-12.821.000	-22.946.000	-14.511.000	-10.924.000	-19.346.000	0	0
Resultat før skat	-99.761.000	-12.484.000	1.881.000	-44.305.000	-1.576.000	-22.134.000	6.779.000	21.654.000
Resultat	-87.791.000	-13.126.000	1.351.000	-35.554.000	1.272.000	-18.756.000	3.508.000	15.009.000
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

12.05.2023

Årsrapport	2022 12.05.2023	2021 12.07.2022	2020 31.05.2021	2019 30.06.2020	2018 04.06.2019	2017 28.03.2018	2016 16.05.2017	2015 09.05.2016
Kortfristede varebeholdninger	34.543.000	29.397.000	29.783.000	20.511.000	21.360.000	19.719.000	17.764.000	21.398.000
Kortfristede tilgodehavender fra salg og tjenesteydelser	263.324.000	267.404.000	283.480.000	261.527.000	239.810.000	220.544.000	244.928.000	212.533.000
Likvider	11.602.000	6.781.000	30.764.000	3.783.000	25.126.000	10.833.000	24.036.000	8.444.000
Kortfristede aktiver	309.469.000	303.582.000	344.027.000	285.821.000	286.296.000	251.096.000	286.728.000	242.375.000
Immaterielle aktiver og goodwill	55.959.000	67.734.000	81.896.000	87.260.000	100.569.000	72.097.000	78.901.000	84.993.000
Finansielle anlægsaktiver	82.030.000	70.430.000	56.936.000	57.868.000	68.060.000	51.744.000	233.000	52.675.000
Materielle aktiver	76.510.000	79.002.000	76.266.000	79.261.000	80.689.000	103.972.000	98.379.000	95.970.000
Langfristede aktiver	214.499.000	217.166.000	215.098.000	224.389.000	249.318.000	227.813.000	232.128.000	233.638.000
Aktiver	523.968.000	520.748.000	559.125.000	510.210.000	535.614.000	478.909.000	518.856.000	476.013.000

Aktiver

12.05.2023

Passiver

12.05.2023

Årsrapport	2022 12.05.2023	2021 12.07.2022	2020 31.05.2021	2019 30.06.2020	2018 04.06.2019	2017 28.03.2018	2016 16.05.2017	2015 09.05.2016
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	59.375.000	144.698.000	152.464.000	156.603.000	192.075.000	186.970.000	212.674.000	207.191.000
Hensatte forpligtelser	2.734.000	1.906.000	2.003.000	1.502.000	4.098.000	6.946.000	0	10.646.000
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	1.992.000	0	0	0	0
Leverandører af varer og tjenesteydelser	99.271.000	68.975.000	45.887.000	34.575.000	40.442.000	39.455.000	24.835.000	14.341.000
Kortfristede forpligtelser	459.189.000	371.038.000	400.989.000	350.763.000	339.441.000	282.241.000	291.667.000	252.335.000
Gældsforpligtelser	464.593.000	376.050.000	406.661.000	353.607.000	339.441.000	284.993.000	306.182.000	258.176.000
Forpligtelser	464.593.000	376.050.000	406.661.000	353.607.000	339.441.000	284.993.000	306.182.000	258.176.000
Passiver	523.968.000	520.748.000	559.125.000	510.210.000	535.614.000	478.909.000	518.856.000	476.013.000

Passiver

12.05.2023

Nøgletal

12.05.2023

Årsrapport	2022 12.05.2023	2021 12.07.2022	2020 31.05.2021	2019 30.06.2020	2018 04.06.2019	2017 28.03.2018	2016 16.05.2017	2015 09.05.2016
Afkastningsgrad	-17,8 %	-3,8 %	2,5 %	-7,6 %	-2,0 %	-1,9 %	1,6 %	Na.
Dækningsgrad	-1,6 %	10,9 %	18,9 %	21,0 %	17,4 %	24,2 %	24,8 %	Na.
Resultatgrad	-19,4 %	-2,7 %	0,3 %	-9,8 %	0,3 %	-4,7 %	0,9 %	3,4 %
Varelagerets omsætningshastighed	13,1	16,4	16,5	17,7	19,3	20,4	22,5	20,6
Egenkapitals-forretning	-147,9 %	-9,1 %	0,9 %	-22,7 %	0,7 %	-10,0 %	1,6 %	7,2 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.	Na.	Na.	Na.	Na.	82,4 %	Na.
Soliditestgrad	11,3 %	27,8 %	27,3 %	30,7 %	35,9 %	39,0 %	41,0 %	43,5 %
Likviditetsgrad	67,4 %	81,8 %	85,8 %	81,5 %	84,3 %	89,0 %	98,3 %	96,1 %

Resultat

12.05.2023

Gæld

12.05.2023

Årsrapport

12.05.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 12.05.2023)

Information om virksomhedens regnskabsklasse:This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (large). The accounting policies applied to these consolidated financial statements and parent financial statements are consistent with those applied last year.

Oplysning om pantsætninger og sikkerhedsstillelser:19 Assets charged and collateralAs collateral for commitments with banks, the following has been deposited: - Owner’s mortage of DKK 20,000 thousand and letter of indemnity of DKK 18,000 thousand secured on the Company’s property Saturnvej 51, Horsens. Current debt is respectively bank debt of DKK 20,098 thousand. The carrying amount of mortgaged properties amounted to DKK 30,167 thousand. As collateral for commitments with banks, the following has been deposited: - Letter of indemnity on movables of DKK 34,000 thousand with a current debt DKK 20,098 thousand. The carrying amount of assets provided as collateral amounted to DKK 32,900 thousand.

Beretning

12.05.2023

Dato for ledelsens godkendelse af årsrapporten:2023-04-28

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Board of Directors and the Executive Board have today considered and approved the annual report of Hamlet Protein A/S for the financial year 01. 01. 2022 - 31. 12. 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesOperating review Hamlet Protein Group HAMLET PROTEIN A/S' business strategy is to develop, produce and sell vegetable specialty protein solutions used in high value-add animal feed for young animals. The company services more than 50 countries from its two production facilities in Horsens, Denmark and Findlay, Ohio, USA and its sales office in Qingdao (China). The subsidiary, HAMLET PROTEIN Inc. , is located in Findlay (Ohio), USA, and handles the production, sales, and distribution of products, primarily to North America, Central America and Asia. The subsidiary, Hamlet (Qingdao) Trading Co. , Ltd. is located in Qingdao (Shandong Province), China, and handles import, sales and distribution to customers in China. As the demand for safe and affordable meat products continues to grow in most regions of the world, so døs the demand for high quality specialty feed protein. HAMLET PROTEIN’s growth is supported by long-term structural mega trends such as population growth, transition from backyard farming towards more industrialized farming practices as well as greater focus on antibiotic free feed practices and feed safety. Especially the North American and Chinese markets have contributed with considerable growth in recent years, driven by the need for continued improvement of farm efficiency, while at the same time reducing or eliminating medication in animal feed. Finally, demand is driven by an increased focus on feed security by reducing the use of animal-based protein diet sources like fishmeal and blood plasma in favor of secure, highly efficient products like HAMLET PROTEIN's soy-based specialty ingredients. HAMLET PROTEIN draws on extensive knowledge of bioavailability, biotechnology, bioconversion, and the practical application of specialty feed ingredients to meet all these demands. Every year, the company runs a large number of tests in its pilot production plant to verify efficacy and customer value. Many innovation projects are managed in partnership with customers, external research institutes and renowned universities. Together, HAMLET PROTEIN aims to lead the way to generate an increased animal performance through a focus on early life nutrition. Ultimately increased efficiency in animal production leads to a reduced carbon footprint for the industry. HAMLET PROTEIN continuously documents the value-adding performance of HAMLET PROTEIN products in numerous international trials at commercial -and research farms and universities and makes that available to (prospective) customers.